GLG News by Healthcare Experts: Lawyers (US)

In addition to the ethical and educational benefits, the cost savings resulting from straight talk with patients and their families that avoids litigation can be extraordinary.  For health care institutions considering this approach -- as they should -- both the effectiveness and the savings may ...

As H.L. Mencken once wrote, "There is always an easy solution to every human problem—neat, plausible, and wrong."   Here, based upon a single, uncited study, the author argues that because a "1 percent change in the production of oil produces a 10 percent change in price," oil prices would...

The debate of uses of genetic information for insurance purposes unfortunately masks the underlying problem:  namely, the failure or inability of Congress to address the failure of the US health care system to allocate risks and costs based on rational policy choices, rather than based upon the...

In discounting  prospects for "winning in court" in litigation arising from losses in the mortgage market, the NYT unfortunately ignores a growing, and perhaps ultimately the primary, form of non-class action private securities litigation--litigation under state securities laws, which generally...

The financial responsibity will lie with Baxter, not the FDA.  Perhaps moral or political responsibility (and fall out) will rest with the FDA, but that is of no help to those harmed by the Heparin.  Their only recourse is to sue the manufacturer.

Under the current administration, the FDA has tried to use drug approval as a shield.  In some cases, the current court has held warning approval to bar lawsuits.  However, this can be remedied by Congress explicitly clarifying that the FDA approval of a drug does not preempt state law....